V2 Harmonized Data Set (HDS)
The V2 HDS has marked a pivotal evolution in the GNPC, representing a thoughtful and strategic expansion of the GNPC’s initial cycle. More than just a growth in numbers, the goal of V2 has been to meaningfully enrich the growing consortium — both by incorporating new samples and by deepening the types of samples and the analyses pursued for sample types.
Throughout this expansion, the GNPC has continued to serve as a collaborative hub, bringing together top scientists at the forefront of neurodegeneration research. Their collective expertise has ensured that each addition to the dataset aligns with the Consortium’s overarching mission: to accelerate the discovery of biomarkers and therapeutic targets in neurodegenerative disease.
Geographic expansion
This phase is actively recruiting additional cohorts to extend the Consortium’s geographic reach and further diversify its sample pool. V1 of the HDS included samples from the US, Germany, the Netherlands, Sweden, Spain, and the UK. V2 aims to bring in at least 10 new cohorts from Central and South America, Asia, and Africa for better global representation.
New analytical power
Beyond scale, V2 has brought new analytical power to the platform, most notably with the integration of Olink's HT and Alamar's NULISA platforms in addition to SomaLogic's expanded 11k assay. By integrating additional proteomic analysis technologies, the GNPC V2 will facilitate expansion and cross-validation of proteomic profiles reflective of the biology of neurodegeneration.
Workstreams and analysis
The increased diversity of the V2 HDS allows for each research question raised within a workstream to be applied broadly across the field of neurodegenerative disorders or to a specific disease area.
V2 HDS current status and release
The GNPC V2 HDS is currently undergoing harmonization and an embargo period offered to the consortia members who contributed to V2. Similar to the V1 HDS, after one year of intra-consortium analysis, the V2 HDS will be accessible to the broader research community as a shared, global resource via the AD Data Initiative’s data platform, the AD Workbench (for approved use/users).
Contact Us
Please contact info@neuroproteome.org with inquiries about joining the Global Neurodegeneration Proteomics Consortium (GNPC) or questions about accessing the resulting data.
